SofWave Medical (SOFW) Stifel 2025 Healthcare Conference summary

Market overview and growth drivers

• Achieved record Q3 2025 revenue of $21.1 million, up 56% year-over-year, with a CAGR of 69% from 2020–2024.

• Over 50% of revenue comes from North America, 30%+ from Asia-Pacific, and 13% from EMEA.

• Strong growth in both consumables (virtual pulses) and capital equipment, with consumables now 40% of revenue.

• GLP-1 patient trends are driving increased demand for skin tightening and muscle toning procedures.

• Brand awareness bolstered by digital marketing, celebrity endorsements, and over a million social media followers.

Business model and profitability

• Recurring revenue model based on virtual consumables with high gross margins and low operating costs.

• Physicians achieve ROI in 4–6 months, with some clinics seeing 150–700% ROI in the first year.

• Net Promoter Score of 86% from internal survey, indicating high customer satisfaction.

• Two consecutive quarters of operating and net income profitability, with $1.9 million operating income in Q3 2025.

• Cash position of $26.5 million, no debt, and positive cash flow generation.

Product innovation and regulatory landscape

• Nine FDA clearances for non-invasive treatments, including unique approval for eyebrow lift.

• Launched new applicators for body treatments and a wireless EMS device for muscle toning.

• Over 14 clinical trials conducted in the U.S. to support efficacy and safety.

• Recent regulatory approval in Japan, with China pending and seen as a major future opportunity.

• Continued product innovation aligns with market trends and patient needs, especially among GLP-1 users.